Skip to main content

Treatment Clinical Trials for Acute Myeloid Leukemia (AML)

Review the acute myeloid leukemia (aml) treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 297

Testing New Therapies for Patients with Acute Myeloid Leukemia Who are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Status: Active
Location: 210 locations
Venetoclax and HMA Treatment of Older and Unfit Adults with FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Status: Active
Location: 220 locations
A Study to Compare Standard Chemotherapy to Therapy with CPX-351 and/or Gilteritinib for Patients with Newly Diagnosed AML with or without FLT3 Mutations
Status: Active
Location: 180 locations
Comparing Cytarabine + Daunorubicin Therapy versus Cytarabine + Daunorubicin + Venetoclax versus Venetoclax + Azacitidine in Younger Patients with Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Status: Active
Location: 171 locations
Comparing New Treatments for People with Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Status: Active
Location: 133 locations
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Status: Active
Location: 34 locations
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Status: Active
Location: 31 locations
Comparing Different Treatment Lengths for Venetoclax in Older People with Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Status: Active
Location: 28 locations
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status: Active
Location: 26 locations
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Status: Active
Location: 29 locations
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Status: Active
Location: 23 locations
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Status: Active
Location: 22 locations
A Study to find the Highest Dose of Imetelstat in Combination with Fludarabine and Cytarabine for Patients with AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
Status: Active
Location: 19 locations
Testing the Anti-cancer Drug, Cirtuvivint, and its Combination with ASTX727 to Improve Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes
Status: Active
Location: 22 locations
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Status: Active
Location: 18 locations
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Status: Active
Location: 17 locations
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Status: Active
Location: 15 locations
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Status: Active
Location: 13 locations
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Status: Active
Location: 16 locations
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination with Filgrastim as a Treatment Option after Hematopoietic Stem Cell Transplant in Children with High-Risk Acute Myeloid Leukemia
Status: Active
Location: 11 locations
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Status: Active
Location: 11 locations
Revumenib, Azacitidine, and Venetoclax for the Treatment of Pediatric and Young Adult Patients with Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
Status: Active
Location: 10 locations
Talazoparib in Combination with Chemotherapy for the Treatment of Pediatric Patients with Relapsed or Refractory AML, the PARPAML Trial
Status: Active
Location: 10 locations
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Status: Active
Location: 11 locations
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Status: Active
Location: 11 locations